Literature DB >> 16473963

Left ventricular hypertrophy in mice with a cardiac-specific overexpression of interleukin-1.

Kenichiro Nishikawa1, Mikoto Yoshida, Masatoshi Kusuhara, Norio Ishigami, Kikuo Isoda, Kohji Miyazaki, Fumitaka Ohsuzu.   

Abstract

Recent studies have identified the importance of proinflammatory cytokines in the development of left ventricular (LV) hypertrophy. However, the precise role of interleukin-1 (IL-1), one of the major proinflammatory cytokines, in the myocardium is not fully understood. In this study, we investigated the pathophysiological consequences of cardiac expression of IL-1 in vivo. We generated mice with a cardiac-specific overexpression of human IL-1alpha. We then analyzed their heart morphology and functions. Histological and echocardiographic analyses revealed concentric LV hypertrophy with preserved LV systolic function in the mice. Our results suggest that myocardial expression of IL-1 is sufficient to cause LV hypertrophy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16473963     DOI: 10.1152/ajpheart.00269.2005

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  18 in total

1.  Paigen diet-fed apolipoprotein E knockout mice develop severe pulmonary hypertension in an interleukin-1-dependent manner.

Authors:  Allan Lawrie; Abdul G Hameed; Janet Chamberlain; Nadine Arnold; Aneurin Kennerley; Kay Hopkinson; Josephine Pickworth; David G Kiely; David C Crossman; Sheila E Francis
Journal:  Am J Pathol       Date:  2011-08-09       Impact factor: 4.307

2.  Pathways involved in interleukin-1β-mediated murine cardiomyocyte apoptosis.

Authors:  Yi Shen; Jie Qin; Peili Bu
Journal:  Tex Heart Inst J       Date:  2015-04-01

Review 3.  Proinflammatory cytokines in heart failure: double-edged swords.

Authors:  Mona Hedayat; Mohammad Jafar Mahmoudi; Noel R Rose; Nima Rezaei
Journal:  Heart Fail Rev       Date:  2010-11       Impact factor: 4.214

Review 4.  Elevated Serum Uric Acid and Cardiovascular Disease: A Review and Potential Therapeutic Interventions.

Authors:  Michael Freilich; Andrew Arredondo; Seyedeh Leila Zonnoor; Isabel M McFarlane
Journal:  Cureus       Date:  2022-03-28

Review 5.  Role of inflammation in the progression of heart failure.

Authors:  Arne Yndestad; Jan Kristian Damås; Erik Øie; Thor Ueland; Lars Gullestad; Pål Aukrust
Journal:  Curr Cardiol Rep       Date:  2007-05       Impact factor: 2.931

6.  Inflammatory pathways are activated during cardiomyocyte hypertrophy and attenuated by peroxisome proliferator-activated receptors PPARalpha and PPARdelta.

Authors:  Pascal J H Smeets; Birgit E J Teunissen; Anna Planavila; Heleen de Vogel-van den Bosch; Peter H M Willemsen; Ger J van der Vusse; Marc van Bilsen
Journal:  J Biol Chem       Date:  2008-08-12       Impact factor: 5.157

7.  Altered interleukin-1 receptor antagonist and interleukin-18 mRNA expression in myocardial tissues of patients with dilatated cardiomyopathy.

Authors:  Elena Westphal; Susanne Rohrbach; Michael Buerke; Hagen Behr; Dorothea Darmer; Rolf-Edgar Silber; Karl Werdan; Harald Loppnow
Journal:  Mol Med       Date:  2008 Jan-Feb       Impact factor: 6.354

Review 8.  The role of IL-1 in the pathogenesis of heart disease.

Authors:  Marcin Bujak; Nikolaos G Frangogiannis
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2009-05-29       Impact factor: 4.291

9.  Independent association of rheumatoid arthritis with increased left ventricular mass but not with reduced ejection fraction.

Authors:  Rebecca L Rudominer; Mary J Roman; Richard B Devereux; Stephen A Paget; Joseph E Schwartz; Michael D Lockshin; Mary K Crow; Lisa Sammaritano; Daniel M Levine; Jane E Salmon
Journal:  Arthritis Rheum       Date:  2009-01

10.  Modulatory effect of interleukin-1α on expression of structural matrix proteins, MMPs and TIMPs in human cardiac myofibroblasts: role of p38 MAP kinase.

Authors:  Neil A Turner; Philip Warburton; David J O'Regan; Stephen G Ball; Karen E Porter
Journal:  Matrix Biol       Date:  2010-07-07       Impact factor: 11.583

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.